Zealand Pharma CEO believes in firm's obesity efforts

Adam Steensberg, the CEO of Zealand Pharma, says that the firm’s three candidates within the indication make the firm an interesting player on the obesity market.
Photo: PR-foto Zealand Pharma
Photo: PR-foto Zealand Pharma
by christian bundgaard, translated by catherine brett

Private wealth manager Bernstein has previously predicted that the obesity market in the US could be worth up to DKK 500bn (USD 72bn) within ten years – and Zealand Pharma wants in.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading